Continued role for ASCT in multiple myeloma
Mené sur 389 patients atteints d'un myélome multiple récemment diagnostiqué, cet essai randomisé international de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité d'un traitement de consolidation (melphalan à haute dose et greffe autologue de cellules souches vs chimiothérapie cyclophosphamide-dexaméthasone combinée avec du lénalidomide) d'une part, et d'un traitement d'entretien à base de lénalidomide, seul ou en combinaison avec la prednisone, d'autre part
In The Lancet Oncology, Francesca Gay and colleagues report findings of an international, multicentre randomised study in patients with newly diagnosed multiple myeloma. Lenalidomide and dexamethasone were administered as induction treatment, followed by randomisation to either cyclophosphamide, lenalidomide, and dexamethasone or high-dose melphalan and autologous stem-cell transplantation (ASCT) as consolidation, and either lenalidomide alone or lenalidomide and prednisone as maintenance. This work builds on a previous study in which lenalidomide induction was followed by randomisation to either oral melphalan, lenalidomide, and prednisone or tandem high-dose melphalan and ASCT.
The Lancet Oncology , commentaire, 2014